Compare Citius Pharmaceuticals Inc (CTXR) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs IDEXX Laboratories, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while IDEXX Laboratories, Inc. trades at $545.49 (market cap $42.65B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2913.3× Citius Pharmaceuticals Inc's market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | IDXX | |
|---|---|---|
Market Cap | $14.64M | $42.65B |
Sector | Health | Health |
52-Week High | $1.82 | $766.68 |
52-Week Low | $0.53 | $514.61 |
Enterprise Value | $10.86M | $43.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
IDXX trades at $564.09, up 0.09% with neutral technical signals. The stock shows strong fundamentals with revenue growth to $4.3B in 2025 and consistent earnings beats. Analyst consensus is bullish (59% Buy) with improving cash flow trends. Recent news highlights AI integration in medical devices and upcoming Q2 2026 earnings.
Outlook remains positive driven by innovation and market leadership in pet healthcare. Risks include high valuation multiples and competitive pressures. Institutional sentiment supports growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
